Northland Securities Predicts Avita Medical Q1 Earnings

Analysts forecast a loss of $0.35 per share for the medical device company's upcoming quarter.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Equities research analysts at Northland Securities have issued their Q1 2026 earnings estimates for Avita Medical Inc. (NASDAQ:RCEL). Northland Securities analyst C. Byrnes forecasts that the company will report a loss of $0.35 per share for the quarter. The consensus estimate for Avita Medical's current full-year earnings is a loss of $0.95 per share.

Why it matters

Avita Medical is a regenerative medicine company focused on developing and commercializing cell-based therapies for acute and chronic wounds. Analysts' earnings predictions provide insight into the company's financial performance and market outlook, which can impact investor sentiment and the stock price.

The details

Northland Securities currently has an "Outperform" rating and a $10.00 target price on Avita Medical's stock. The firm also issued estimates for the company's Q2 2026 earnings at a loss of $0.32 per share, Q3 2026 earnings at a loss of $0.29 per share, Q4 2026 earnings at a loss of $0.23 per share, FY2026 earnings at a loss of $1.20 per share, and FY2027 earnings at a loss of $0.70 per share.

  • Northland Securities issued their Q1 2026 earnings estimates for Avita Medical on Thursday, March 5th.

The players

Northland Securities

An equities research firm that has issued earnings estimates and a rating for Avita Medical.

C. Byrnes

A Northland Securities analyst who forecasts Avita Medical will report a loss of $0.35 per share in Q1 2026.

Avita Medical Inc.

A regenerative medicine company focused on developing and commercializing cell-based therapies for acute and chronic wounds.

Got photos? Submit your photos here. ›

What they’re saying

“Northland Securities currently has a "Outperform" rating and a $10.00 target price on the stock.”

— Northland Securities, Equities research firm (MarketBeat)

The takeaway

Avita Medical's upcoming earnings report will be closely watched by investors as the company continues to develop its regenerative medicine technologies. The analyst predictions provide insight into the company's near-term financial outlook, which could impact the stock price and investor sentiment.